| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MBNL2 |
| Uniprot No | Q5VZF2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-373aa |
| 活性数据 | MALNVAPVRDTKWLTLEVCRQFQRGTCSRSDEECKFAHPPKSCQVENGRVIACFDSLKGRCSRENCKYLHPPTHLKTQLEINGRNNLIQQKTAAAMLAQQMQFMFPGTPLHPVPTFPVGPAIGTNTAISFAPYLAPVTPGVGLVPTEILPTTPVIVPGSPPVTVPGSTATQKLLRTDKLEVCREFQRGNCARGETDCRFAHPADSTMIDTSDNTVTVCMDYIKGRCMREKCKYFHPPAHLQAKIKAAQHQANQAAVAAQAAAAAATVMAFPPGALHPLPKRQALEKSNGTSAVFNPSVLHYQQALTSAQLQQHAAFIPTGSVLCMTPATSIDNSEIISRNGMECQESALRITKHCYCTYYPVSSSIELPQTAC |
| 分子量 | 66.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MBNL2蛋白的假设参考文献示例，基于该领域常见研究方向总结：
---
1. **文献名称**：**"Expression and Functional Analysis of Recombinant Human MBNL2 in RNA Splicing Regulation"**
**作者**：Smith J., Brown K., *et al.*
**摘要**：本研究报道了在HEK293细胞中高效表达并纯化重组人MBNL2蛋白的方法。通过体外RNA结合实验和剪接报告系统，证实了MBNL2对特定RNA靶标(如肌细胞前信使RNA)的亲和力及剪接调控功能，为研究其病理机制提供工具。
2. **文献名称**：**"Structural Insights into MBNL2 Zinc Finger Domains and RNA Interaction Motifs"**
**作者**：Jones R., Tanaka M., *et al.*
**摘要**：通过X射线晶体学解析了重组人MBNL2蛋白的锌指结构域三维结构，揭示了其与RNA结合的分子机制。突变实验证明特定氨基酸残基对维持RNA结合活性的关键作用，为开发纠正异常剪接的小分子奠定基础。
3. **文献名称**：**"Rescue of Splicing Defects in Myotonic Dystrophy Models by Recombinant MBNL2 Delivery"**
**作者**：Zhang L., Wei Y., *et al.*
**摘要**：在肌强直性营养不良细胞模型中，外源性重组MBNL2蛋白有效恢复了病理性RNA foci导致的剪接异常，并部分逆转了细胞分化障碍。研究提示MBNL2替代疗法的潜在治疗价值。
4. **文献名称**：**"Dynamic Interactions Between MBNL2 and CELF1 Regulate Muscle Development"**
**作者**：Lee S., Garcia-Perez A., *et al.*
**摘要**：本文发现重组MBNL2蛋白通过拮抗CELF1蛋白的活性调控肌肉细胞分化，阐明了二者在时序性剪接调控中的竞争机制，为理解发育相关剪接失调提供新视角。
---
注：上述文献为假设示例，实际研究中请通过学术数据库(如PubMed、Google Scholar)以“recombinant MBNL2”、“MBNL2 protein function”等关键词检索。
Recombinant human MBNL2 protein is derived from the Muscleblind-like (MBNL) family of RNA-binding proteins, which play critical roles in regulating alternative splicing, RNA localization, and stability. MBNL2. along with MBNL1 and MBNL3. contains conserved zinc finger domains that mediate interactions with RNA, particularly targeting specific sequences in pre-mRNAs to control splicing decisions. It is broadly expressed in tissues, including muscle and brain, and is essential for normal development and cellular differentiation. Dysregulation of MBNL2 is linked to myotonic dystrophy (DM), a multisystemic disorder caused by CUG/CCUG repeat expansions that sequester MBNL proteins, leading to splicing defects and muscle/neurological dysfunction.
Recombinant MBNL2 is typically produced in bacterial or eukaryotic expression systems to study its molecular interactions, structural properties, and therapeutic potential. It enables researchers to investigate mechanisms of RNA binding, splice regulation, and MBNL2’s role in mitigating disease-related splicing errors. Additionally, recombinant MBNL2 aids in drug discovery efforts, such as screening compounds that disrupt pathological RNA-protein aggregates in DM. Its use in cellular and animal models has provided insights into restoring normal splicing activity, highlighting its significance as both a research tool and a potential therapeutic agent for RNA-mediated diseases.
×
